Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter Blume-Jensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 1.93
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.97
Financials
Net Income
$-17.96MEBITDA
$-17.56MFree Cash Flow
$-14.95MEPS (diluted)
$-0.43Shares Outstanding (diluted)
41.84M+224.1%Operating Expenses
$18.67MCash & Debt
$89.96MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-77.91M | $-2.02 |
| 2024 | $0.00 | $-80.56M | $-2.10 |
| 2023 | $0.00 | $-60.39M | $-2.74 |
| 2022 | $0.00 | $-31.17M | $-1.42 |
| 2021 | $0.00 | $-16.24M | $-1.26 |
| 2020 | $0.00 | $-5.31M | $-0.41 |
Valuation
ACRVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
125+4.17%Social Signal Score
Mentions (4)
- Newszacks.com·23d ago·Positive
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·35d ago·Positive
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? Acrivon Therapeutics, Inc. (ACRV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACRV's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy
View source ↗ - Newszacks.com·45d ago·Positive
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.45 per share
Typical surprise +10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.43 vs $-0.50beat
- Wed, May 13$-0.49 vs $-0.49beat
- Thu, Mar 19$-0.49 vs $-0.49beat
- Thu, Nov 13$-0.47 vs $-0.57beat
- Wed, Aug 13$-0.55 vs $-0.57beat
- Wed, May 14$-0.51 vs $-0.57beat
Estimates and results for ACRV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACRV officers and directors.
- Bought
- $114k
- Sold
- $3.8m
3 trades
14 trades
- Blume-jensen Petersold
- Peterson Katharinesold
- Miller Marysold
- Gamelin Ericksold
- Devroe Ericsold
- Blume-jensen Petersold
- Blume-jensen Petersold
- Levy Adam D.sold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACRV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.